8 December 2020 - NICE has published preliminary guidelines backing use of AstraZeneca's Calquence (acalabrutinib) as an NHS funded treatment for chronic lymphocytic leukaemia.

The Institute is proposing to allow the use of acalabrutinib for adults with untreated chronic lymphocytic leukaemia if they have a 17p deletion or TP53 mutation, and also as an option for those who have had at least one previous treatment, but only if ibrutinib is their only suitable treatment option as a further restriction.

Read Pharma Times article